Further studies are warranted to validate this potential biomarker to stratify colon cancer patients for response to 5-FU-based chemotherapy in the clinic and to dissect the putative essential function of MACROD2 with respect to therapy resistance. This evidence concerns the gene MACROD2 and colonic neoplasm.